Efficacy and safety results from a randomized, phase II trial of neoadjuvant capecitabine plus epirubicin plus cyclophosphamide vs 5-FU + epirubicin plus cyclophosphamide in operable breast cancer

被引：0
|
作者：
Roche, H.
Penault-Llorca, F.
Berton, Rigaud D.
Tubiana, Mathieu N.
Ferrero, J. M.
Coudert, B.
Mousseau, M.
Monnier, A.
Orfuevre, H.
Audhuy, B.
Rotarski, M.
Homokos, H.
Fumoleau, P.
机构：
[1] Inst Claudius Regaud, Toulouse, France
[2] Ctr Jean Perrin, Clermont Ferrand, France
[3] Ctr Rene Gauducheau, St Herblain, France
[4] Hop Dupuytren, Limoges, France
[5] Ctr Antoine Lacassagne, F-06054 Nice, France
[6] Ctr Georges Francois Leclerc, Dijon, France
[7] CHU Grenoble, La Tronche, France
[8] CH Montbeliard, Montbeliard, France
[9] CH Fleyriat, Bourg En Bresse, France
[10] Hop Louis Pasteur, Colmar, France
[11] Ctr Oncol Du Pays Basque, Bayonne, France
[12] Roche Neuilly, Neuilly Sur Seine, France
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2007年 / 106卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S225 / S225
页数：1
相关论文
共 50 条
  • [31] Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide plus filgrastim as neoadjuvant treatment in locally advanced breast cancer: An EORTC-NCIC-SAKK multicenter study
    Therasse, P
    Mauriac, L
    Welnicka-Jaskiewicz, M
    Bruning, P
    Cufer, T
    Bonnefoi, H
    Tomiak, E
    Pritchard, KI
    Hamilton, A
    Piccart, MJ
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (05) : 843 - 850
  • [32] The Efficacy and Toxicity of Neoadjuvant Chemotherapy Regimens of Epirubicin Plus Cyclophosphamide Followed by Docetaxel or Paclitaxel in Female Breast Cancer Patients
    Wu, Xian
    Ye, Chaoran
    Wang, Xingmeng
    Cai, Ruyu
    Yang, Junzhe
    Yu, Xiafei
    Zhou, Yi
    Shen, Li
    Zhu, Yanhui
    Liu, Xiaoan
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 1517 - 1527
  • [33] Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group
    Hans-Joachim Lück
    Andreas Du Bois
    Sibylle Loibl
    Iris Schrader
    Jens Huober
    Volker Heilmann
    Matthias Beckmann
    Ann Stähler
    Christian Jackisch
    Michael Hubalek
    Barbara Richter
    Elmar Stickeler
    Holger Eidtmann
    Christoph Thomssen
    Michael Untch
    Kerstin Wollschläger
    Tibor Schuster
    Gunter von Minckwitz
    Breast Cancer Research and Treatment, 2013, 139 : 779 - 787
  • [34] Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group
    Lueck, Hans-Joachim
    Du Bois, Andreas
    Loibl, Sibylle
    Schrader, Iris
    Huober, Jens
    Heilmann, Volker
    Beckmann, Matthias
    Staehler, Ann
    Jackisch, Christian
    Hubalek, Michael
    Richter, Barbara
    Stickeler, Elmar
    Eidtmann, Holger
    Thomssen, Christoph
    Untch, Michael
    Wollschlaeger, Kerstin
    Schuster, Tibor
    von Minckwitz, Gunter
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 139 (03) : 779 - 787
  • [35] Doxorubicin plus ifosfamide as salvage treatment for patients with advanced breast cancer refractory to epirubicin plus cyclophosphamide
    Polyzos, A
    Kosmas, C
    Tsavaris, N
    Markopoulos, C
    Kalahanis, N
    Papadopoulos, O
    Arnaouti, T
    Sfikakis, PP
    CLINICAL DRUG INVESTIGATION, 2000, 19 (05) : 349 - 355
  • [36] Doxorubicin plus Ifosfamide as Salvage Treatment for Patients with Advanced Breast Cancer Refractory to Epirubicin plus Cyclophosphamide
    Aristidis Polyzos
    C. Kosmas
    N. Tsavaris
    C. Markopoulos
    N. Kalahanis
    O. Papadopoulos
    T. Arnaouti
    P. P. Sfikakis
    Clinical Drug Investigation, 2000, 19 : 349 - 355
  • [37] Epirubicin, cyclophosphamide, and UFT plus oral calcium folinate in advanced breast cancer
    Smith, IE
    ONCOLOGY-NEW YORK, 1999, 13 (07): : 82 - 85
  • [38] A phase II trial of neoadjuvant docetaxel/cyclophosphamide followed by epirubicin/cyclophosphamide for triple-negative breast cancer
    Tanaka, N.
    Hirano, A.
    Inoue, H.
    Ogura, K.
    Hattori, A.
    Jibiki, N.
    Yukawa, H.
    Matsuoka, A.
    Kodera, A.
    Kamimura, M.
    Naritaka, Y.
    Shimizu, T.
    CANCER RESEARCH, 2017, 77
  • [39] UFT/leucovorin plus bolus epirubicin and cyclophosphamide in advanced/metastatic breast cancer
    Gregory, RK
    Johnston, SRD
    Smith, IE
    Miles, D
    ONCOLOGY-NEW YORK, 2000, 14 (10): : 47 - 49
  • [40] A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer
    Natoli, C.
    Cianchetti, E.
    Tinari, N.
    Angelucci, D.
    Grassadonia, A.
    Zilli, M.
    Ficorella, C.
    Ricevuto, E.
    Grossi, S.
    De Tursi, M.
    Carella, C.
    Rispoli, A. I.
    Iacobelli, S.
    ANNALS OF ONCOLOGY, 2007, 18 (06) : 1015 - 1020
12345